AbbVie
ABBV
#27
Rank
NZ$658.32 B
Marketcap
NZ$372.19
Share price
1.78%
Change (1 day)
2.54%
Change (1 year)

The biotechnology and pharmaceutical company Abbvie, spelled AbbVie, was founded in 2013 as a spin-off from Abbott Laboratories and is traded on the NYSE stock exchange in the S&P 100 index under the symbol โ€œABBVโ€.

AbbVie (ABBV) - Cash on Hand

Cash on Hand as of December 2025 : NZ$9.18 Billion

According to AbbVie's latest financial reports the company has NZ$9.18 Billion in cash and cash equivalents.
A companyโ€™s cash on hand also refered as cash/cash equivalents (CCE) and Short-term investments, is the amount of accessible money a business has.

AbbVie - Cash on Hand chart (from 2011 to 2025)

Cash on Hand by year

Year Cash on Hand Change
2025-12-31NZ$9.07 B-7.84%
2024-12-31NZ$9.84 B-51.4%
2023-12-31NZ$20.26 B39.42%
2022-12-31NZ$14.53 B1.01%
2021-12-31NZ$14.39 B22.47%
2020-12-31NZ$11.75 B-80.18%
2019-12-31NZ$59.28 B393.28%
2018-12-31NZ$12.01 B-12.81%
2017-12-31NZ$13.78 B48.65%
2016-12-31NZ$9.27 B-24.51%
2015-12-31NZ$12.28 B14.93%
2014-12-31NZ$10.68 B-11.24%
2013-12-31NZ$12.04 B24.19%
2012-12-31NZ$9.69 B1058.81%
2011-12-31NZ$0.83 B5890.66%
2010-12-31NZ$13.96 M

Cash on Hand for similar companies or competitors

Company Cash on Hand differencediff. Country
Pfizer
PFE
NZ$23.74 B 158.63%๐Ÿ‡บ๐Ÿ‡ธ USA
Eli Lilly
LLY
NZ$12.69 B 38.25%๐Ÿ‡บ๐Ÿ‡ธ USA
Amgen
AMGN
NZ$15.94 B 73.65%๐Ÿ‡บ๐Ÿ‡ธ USA
Biogen
BIIB
NZ$6.66 B-27.42%๐Ÿ‡บ๐Ÿ‡ธ USA
Gilead Sciences
GILD
NZ$16.78 B 82.86%๐Ÿ‡บ๐Ÿ‡ธ USA
Bristol-Myers Squibb
BMY
NZ$18.63 B 103.02%๐Ÿ‡บ๐Ÿ‡ธ USA
AstraZeneca
AZN
NZ$9.98 B 8.79%๐Ÿ‡ฌ๐Ÿ‡ง UK
GSK plc
GSK
NZ$7.42 B-19.07%๐Ÿ‡ฌ๐Ÿ‡ง UK
Neurocrine Biosciences
NBIX
NZ$2.58 B-71.84%๐Ÿ‡บ๐Ÿ‡ธ USA